BRST5:Secretory carcinoma - Revision history

Bailey.Glen at 17:52, 3 July 2025

2025-07-03T17:52:48Z

← Older revision		Revision as of 12:52, 3 July 2025
Line 28:		Line 28:
	\|}		\|}

	~~==WHO Essential and Desirable Genetic Diagnostic Criteria==~~
	~~{\| class="wikitable"~~
	\|+
	\|WHO Essential Criteria (Genetics)*
	\|
	\|-
	\|WHO Desirable Criteria (Genetics)*
	~~\|''ETV6''::''NTRK3'' fusion~~
	\|-
	~~\|Other Classification~~
	\|
	\|}
	<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
	==Related Terminology==		==Related Terminology==

Kgeiersbach: formatting

2025-06-21T19:20:29Z

formatting

← Older revision		Revision as of 14:20, 21 June 2025
Line 55:		Line 55:
	[[File:ETV6-NTRK3 fusion diagram.tif\|left\|frameless\|655x655px\|Gene fusion diagram showing the canonical breakpoints in exon 5 of ''ETV6'' (NM_001987) and exon 15 of ''NTRK3'' (NM_001012338). Alternate fusion breakpoints include exon 4 of ''ETV6'' and exon 14 of ''NTRK3''.]]		[[File:ETV6-NTRK3 fusion diagram.tif\|left\|frameless\|655x655px\|Gene fusion diagram showing the canonical breakpoints in exon 5 of ''ETV6'' (NM_001987) and exon 15 of ''NTRK3'' (NM_001012338). Alternate fusion breakpoints include exon 4 of ''ETV6'' and exon 14 of ''NTRK3''.]]
	<br />		<br />








	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
Line 123:		Line 131:


	==Gene Mutations (SNV/INDEL) ==		==Gene Mutations (SNV/INDEL)==
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
Line 173:		Line 181:

	Prior Author(s):		Prior Author(s):
	==References ==		==References==
	<references />		<references />
	<nowiki>*</nowiki>''Citation of this Page'': “Secretory carcinoma”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/BRST5:Secretory carcinoma</nowiki>.		<nowiki>*</nowiki>''Citation of this Page'': “Secretory carcinoma”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/BRST5:Secretory carcinoma</nowiki>.

Bailey.Glen at 22:12, 25 May 2025

2025-05-25T22:12:16Z

← Older revision		Revision as of 17:12, 25 May 2025
Line 87:		Line 87:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Chr #!!~~'''~~Gain, Loss, Amp, LOH~~'''~~!!~~'''~~Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]~~'''~~!!~~'''~~Relevant Gene(s)~~'''~~		!Chr #!!Gain, Loss, Amp, LOH!!Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]!!Relevant Gene(s)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|		\|
Line 108:		Line 108:
	!Chromosomal Pattern		!Chromosomal Pattern
	!Molecular Pathogenesis		!Molecular Pathogenesis
	!~~'''~~Prevalence -~~'''~~		!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|		\|
Line 126:		Line 126:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Gene!!~~'''~~Genetic Alteration~~'''~~!!~~'''~~Tumor Suppressor Gene, Oncogene, Other~~'''~~!!~~'''~~Prevalence -~~'''~~		!Gene!!Genetic Alteration!!Tumor Suppressor Gene, Oncogene, Other!!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T ~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|		\|

Bailey.Glen at 20:35, 25 May 2025

2025-05-25T20:35:28Z

← Older revision		Revision as of 15:35, 25 May 2025
Line 42:		Line 42:
	<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].		<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
	==Related Terminology==		==Related Terminology==

	{\| class="wikitable"		{\| class="wikitable"
	\|+		\|+
	\|Acceptable		\|Acceptable
	\|		\|N/A
	\|-		\|-
	\|Not Recommended		\|Not Recommended
	\|		\|Juvenile breast carcinoma {4285563}
	\|}		\|}

Kgeiersbach: added gene fusion diagram

2025-04-16T16:32:11Z

added gene fusion diagram

← Older revision		Revision as of 11:32, 16 April 2025
Line 1:		Line 1:
	{{DISPLAYTITLE:Secretory carcinoma}}		{{DISPLAYTITLE:Secretory carcinoma}}

	[[BRST5:Table_of_Contents\|Breast Tumours (WHO Classification, 5th ed.)]]		[[BRST5:Table_of_Contents\|Breast Tumours (WHO Classification, 5th ed.)]]

	~~{{Under Construction}}~~

	<span style="color:#0070C0">(''General Instructions – The focus of these pages is the clinically significant genetic alterations in each disease type. This is based on up-to-date knowledge from multiple resources such as PubMed and the WHO classification books. The CCGA is meant to be a supplemental resource to the WHO classification books; the CCGA captures in a continually updated wiki-stye manner the current genetics/genomics knowledge of each disease, which evolves more rapidly than books can be revised and published. If the same disease is described in multiple WHO classification books, the genetics-related information for that disease will be consolidated into a single main page that has this template (other pages would only contain a link to this main page). Use [https://www.genenames.org/ <u>HUGO-approved gene names and symbols</u>] (italicized when appropriate), [https://varnomen.hgvs.org/ <u>HGVS-based nomenclature for variants</u>], as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them (add N/A if not applicable in the table and delete the examples); to add (or move) a row or column in a table, click nearby within the table and select the > symbol that appears. Please do not delete or alter the section headings. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see'' </span><u>''[[Author_Instructions]]''</u><span style="color:#0070C0"> ''and [[Frequently Asked Questions (FAQs)\|<u>FAQs</u>]] as well as contact your [[Leadership\|<u>Associate Editor</u>]] or [mailto:CCGA@cancergenomics.org <u>Technical Support</u>].)''</span>
	==Primary Author(s)*==		==Primary Author(s)*==
	Hui Chen, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, USA		Hui Chen, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Line 32:		Line 29:

	==WHO Essential and Desirable Genetic Diagnostic Criteria==		==WHO Essential and Desirable Genetic Diagnostic Criteria==


	<span style="color:#0070C0">(''Instructions: The table will have the diagnostic criteria from the WHO book <u>autocompleted</u>; remove any <u>non</u>-genetics related criteria. If applicable, add text about other classification'' ''systems that define this entity and specify how the genetics-related criteria differ.'')</span>
	{\| class="wikitable"		{\| class="wikitable"
	\|+		\|+
Line 41:		Line 35:
	\|-		\|-
	\|WHO Desirable Criteria (Genetics)*		\|WHO Desirable Criteria (Genetics)*
	\|		\|''ETV6''::''NTRK3'' fusion
	\|-		\|-
	\|Other Classification		\|Other Classification
Line 48:		Line 42:
	<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].		<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
	==Related Terminology==		==Related Terminology==


	~~<span style="color:#0070C0">(''Instructions: The table will have the related terminology from the WHO <u>autocompleted</u>.)''</span>~~
	{\| class="wikitable"		{\| class="wikitable"
	\|+		\|+
Line 61:		Line 52:

	==Gene Rearrangements==		==Gene Rearrangements==
			[[File:ETV6-NTRK3 fusion diagram.tif\|left\|frameless\|655x655px\|Gene fusion diagram showing the canonical breakpoints in exon 5 of ''ETV6'' (NM_001987) and exon 15 of ''NTRK3'' (NM_001012338). Alternate fusion breakpoints include exon 4 of ''ETV6'' and exon 14 of ''NTRK3''.]]
	<br />		<br />
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
Line 130:		Line 122:


	==Gene Mutations (SNV/INDEL)==		==Gene Mutations (SNV/INDEL) ==
	~~<br />~~
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
Line 178:		Line 169:

	<br />		<br />
	==Notes==		==Notes==


	<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the [[Leadership\|''<u>Associate Editor</u>'']] or other CCGA representative. When pages have a major update, the new author will be acknowledged at the beginning of the page, and those who contributed previously will be acknowledged below as a prior author.

	Prior Author(s):		Prior Author(s):
	==References==		==References ==


	(use the "Cite" icon at the top of the page) <span style="color:#0070C0">(''Instructions: Add each reference into the text above by clicking where you want to insert the reference, selecting the “Cite” icon at the top of the wiki page, and using the “Automatic” tab option to search by PMID to select the reference to insert. If a PMID is not available, such as for a book, please use the “Cite” icon, select “Manual” and then “Basic Form”, and include the entire reference. To insert the same reference again later in the page, select the “Cite” icon and “Re-use” to find the reference; DO NOT insert the same reference twice using the “Automatic” tab as it will be treated as two separate references. The reference list in this section will be automatically generated and sorted''</span><span style="color:#0070C0">''.''</span><span style="color:#0070C0">)</span>

	~~<br />~~
	<references />		<references />
	<nowiki>*</nowiki>''Citation of this Page'': “Secretory carcinoma”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/BRST5:Secretory carcinoma</nowiki>.		<nowiki>*</nowiki>''Citation of this Page'': “Secretory carcinoma”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/BRST5:Secretory carcinoma</nowiki>.

Bailey.Glen at 13:39, 27 March 2025

2025-03-27T13:39:45Z

← Older revision		Revision as of 08:39, 27 March 2025
Line 1:		Line 1:
	{{DISPLAYTITLE:Secretory carcinoma}}		{{DISPLAYTITLE:Secretory carcinoma}}

	[[BRST5:Table_of_Contents\|Breast Tumours (WHO Classification, 5th ed.)]]		[[BRST5:Table_of_Contents\|Breast Tumours (WHO Classification, 5th ed.)]]

Bailey.Glen: Repeat columns removed

2025-03-27T13:39:12Z

Repeat columns removed

Show changes

Bailey.Glen at 18:10, 24 March 2025

2025-03-24T18:10:18Z

Show changes

Kgeiersbach at 04:37, 9 January 2025

2025-01-09T04:37:32Z

← Older revision		Revision as of 23:37, 8 January 2025
Line 67:		Line 67:
	\|D, P, T		\|D, P, T
	\|		\|
	\|The ''ETV6''::''NTRK3'' fusion is diagnostic of secretory carcinoma in the appropriate morphologic and clinical context.<ref>{{Cite journal\|last=Arce\|first=C.\|last2=Cortes-Padilla\|first2=D.\|last3=Huntsman\|first3=D. G.\|last4=Miller\|first4=M. A.\|last5=Dueñnas-Gonzalez\|first5=A.\|last6=Alvarado\|first6=A.\|last7=Pérez\|first7=V.\|last8=Gallardo-Rincón\|first8=D.\|last9=Lara-Medina\|first9=F.\|date=2005-06-17\|title=Secretory carcinoma of the breast containing the ETV6-NTRK3 fusion gene in a male: case report and review of the literature\|url=https://pubmed.ncbi.nlm.nih.gov/15963235\|journal=World Journal of Surgical Oncology\|volume=3\|pages=35\|doi=10.1186/1477-7819-3-35\|issn=1477-7819\|pmc=1184104\|pmid=15963235}}</ref><ref>{{Cite journal\|last=Jacob\|first=John Doromal\|last2=Hodge\|first2=Caitlin\|last3=Franko\|first3=Jan\|last4=Pezzi\|first4=Christopher M.\|last5=Goldman\|first5=Charles D.\|last6=Klimberg\|first6=Vicki Suzanne\|date=2016-06\|title=Rare breast cancer: 246 invasive secretory carcinomas from the National Cancer Data Base\|url=https://pubmed.ncbi.nlm.nih.gov/27040042\|journal=Journal of Surgical Oncology\|volume=113\|issue=7\|pages=721–725\|doi=10.1002/jso.24241\|issn=1096-9098\|pmid=27040042}}</ref> This fusion is responsive to TRK inhibitor therapies such as larotrectinib abd entrectinib.		\|The ''ETV6''::''NTRK3'' fusion is diagnostic of secretory carcinoma in the appropriate morphologic and clinical context.<ref>{{Cite journal\|last=Arce\|first=C.\|last2=Cortes-Padilla\|first2=D.\|last3=Huntsman\|first3=D. G.\|last4=Miller\|first4=M. A.\|last5=Dueñnas-Gonzalez\|first5=A.\|last6=Alvarado\|first6=A.\|last7=Pérez\|first7=V.\|last8=Gallardo-Rincón\|first8=D.\|last9=Lara-Medina\|first9=F.\|date=2005-06-17\|title=Secretory carcinoma of the breast containing the ETV6-NTRK3 fusion gene in a male: case report and review of the literature\|url=https://pubmed.ncbi.nlm.nih.gov/15963235\|journal=World Journal of Surgical Oncology\|volume=3\|pages=35\|doi=10.1186/1477-7819-3-35\|issn=1477-7819\|pmc=1184104\|pmid=15963235}}</ref><ref>{{Cite journal\|last=Jacob\|first=John Doromal\|last2=Hodge\|first2=Caitlin\|last3=Franko\|first3=Jan\|last4=Pezzi\|first4=Christopher M.\|last5=Goldman\|first5=Charles D.\|last6=Klimberg\|first6=Vicki Suzanne\|date=2016-06\|title=Rare breast cancer: 246 invasive secretory carcinomas from the National Cancer Data Base\|url=https://pubmed.ncbi.nlm.nih.gov/27040042\|journal=Journal of Surgical Oncology\|volume=113\|issue=7\|pages=721–725\|doi=10.1002/jso.24241\|issn=1096-9098\|pmid=27040042}}</ref><ref>{{Cite journal\|last=Li\|first=Dali\|last2=Xiao\|first2=Xiuying\|last3=Yang\|first3=Wentao\|last4=Shui\|first4=Ruohong\|last5=Tu\|first5=Xiaoyu\|last6=Lu\|first6=Hongfen\|last7=Shi\|first7=Daren\|date=2012-04\|title=Secretory breast carcinoma: a clinicopathological and immunophenotypic study of 15 cases with a review of the literature\|url=https://pubmed.ncbi.nlm.nih.gov/22157932\|journal=Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc\|volume=25\|issue=4\|pages=567–575\|doi=10.1038/modpathol.2011.190\|issn=1530-0285\|pmid=22157932}}</ref> This fusion is responsive to TRK inhibitor therapies such as larotrectinib abd entrectinib.
	\|-		\|-
	\|		\|
Line 166:		Line 166:

	<br />		<br />
			<references />

Kgeiersbach at 04:35, 9 January 2025

2025-01-09T04:35:04Z

Show changes